Regeneron Says Early-Stage Results Positive for REGN1979 in Lymphoma
14 June 2019 - 9:56PM
Dow Jones News
By Michael Dabaie
Regeneron Pharmaceuticals Inc. (REGN) said results were positive
from early-stage data for REGN1979 in patients with relapsed or
refractory B-cell non-Hodgkin lymphoma.
The company said there was a 93% overall response and 71%
complete response rates in follicular lymphoma grades 1 to 3a
treated with REGN1979 5 mg to 320 mg.
There was a 57% overall response rate in diffuse large B-cell
lymphoma treated with REGN1979 80 mg to 160 mg, all of which were
complete responses, including two complete responses in four
patients whose disease had progressed after CAR-T treatment, the
company said.
"We are very encouraged by the continued high response rates
observed with REGN1979 in both relapsed or refractory diffuse large
B-cell lymphoma and follicular lymphoma, cancers with typically
poor outcomes," said Israel Lowy, head of clinical and
translational sciences, oncology at Regeneron.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
June 14, 2019 07:41 ET (11:41 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From Jul 2023 to Jul 2024